ABSTRACT To address the sedimentation and instability of cement slurries under the high‐temperature and high‐pressure conditions of deep and ultra‐deep well cementing, a novel organic–inorganic hybrid suspension stabilizer, LXCH, was designed and synthesized. Four functional monomers were copolymerized in situ with modified nano‐montmorillonite to construct a hybrid framework combining rigid inorganic components with flexible polymer chains. The target structure was confirmed by Fourier transform infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, and X‐ray photoelectron spectroscopy, while thermogravimetric analysis demonstrated excellent thermal stability, with no obvious degradation below 282°C. At 210°C and 90 MPa, the incorporation of LXCH significantly improved slurry suspension stability, resulting in a hardened cement column density difference below 0.04 g/cm 3 , without adversely affecting rheological properties, thickening behavior, or compressive strength. Rheological frequency sweeps, hydrodynamic radius and zeta potential measurements, environmental scanning electron microscopy observations, and molecular dynamics simulations revealed a dual‐network stabilization mechanism. Partial polymer crosslinking forms an initial chemical network at relatively low temperatures, while hydrophobic association at elevated temperatures generates a dynamic physical network. Together with electrostatic adsorption and steric hindrance, these networks effectively maintain slurry stability, providing a promising strategy for high‐performance stabilizers for deep and ultra‐deep well cementing.

Annular channeling during cementing is a critical challenge, primarily caused by gel strength loss and volumetric shrinkage of cement slurry in the plastic phase. To reduce the risk of annular channeling, this study synthesized a microencapsulated slow-release expansive agent (SRNM) using azodicarbonamide (ADC) as the core and nano-SiO2/ethyl cellulose (EC) as the shell. The characteristics, gas release performance, and application effect in cement slurry were systematically investigated. The results confirm that the EC-SiO2 composite shell was successfully coated onto the surface of ADC, forming SRNM with a distinct core-shell structure. Sustained-release tests in saturated Ca(OH)2solution revealed three release behaviors of SRNM corresponding to the induction, acceleration, and deceleration stages of cement hydration, which followed zero-order, Logistic, and first-order kinetic models, respectively. Notably, the main gas-release stage of SRNM coincided well with the plastic phase of cement hydration, enabling effective control of gas-generation timing. Cement slurry incorporating SRNM exhibited significant expansion during the plastic phase, effectively compensating for volumetric shrinkage; at a dosage of 0.6 wt%, the volumetric expansion of the cement slurry reached 6.38 %. Meanwhile, the outward expansion stress generated by SRNM offset the loss of hydrostatic pressure caused by the development of static gel strength, thereby maintaining wellbore pressure stability and mitigating flow migration. Bonding strength tests showed that the bonding strength of cement stone containing SRNM increased by 160 % compared

The cement sheath formed during well cementing is inherently brittle and prone to micro-cracking, which can impair zonal isolation and reduce hydrocarbon productivity. To address this, we synthesized epoxy resin-cured particles engineered to enhance the elasticity and toughness of the set cement. First, a hyperbranched polymer (BPG) was synthesized from 4,4 '-dihydroxydiphenyl-sulfone (BPS), glycerol triglycidyl ether (GTE), and poly (ethylene glycol) diglycidyl ether (PEGDGE). BPG was dispersed in epoxy resin E54 and, by a phase-inversion route with DMP-30 as curing agent, converted into modified epoxy resin-cured particles (BPGE). The molecular structures of BPG and BPGE were verified spectroscopically. Particle morphology, surface wettability, thermal stability, and dynamic thermo-mechanical behavior were then examined, and the effect of BPGE on cement mechanical properties was evaluated. The results show that BPG is the target product for design. BPGE is quasispherical (D50 = 55.9 mu m) and intrinsically hydrophilic; No thermal decomposition occurs below 335 degrees C. BPGE has a lower storage modulus, which can effectively improve the elasticity and toughness of cement stone. When the dosage is 6 bwoc%, the elastic modulus of cement stone decreases to 5.77 GPa (-36.6 % vs. blank control group), peak strain rises to 0.83 %, while compressive strength is scarcely affected. The mechanism by which BPGE improves the elasticity and toughness of cement stone lies in its molecular cavity structure and flexible chains contained in the supramolecular polymer. Its own elastic deformation ability and toughness have been enhanced, allowing it to absorb and dissipate stress when subjected to external loads, thereby improving the crack resistance of cement stone. Therefore, hyperbranched polymer-modified epoxy resin-cured particles pro-vide a new approach to improving the mechanical properties of cement sheath in well cementing.

Annular pressure in oil and gas wells, often caused by the brittle failure of Portland cement sheaths, poses significant safety and economic risks. To address this challenge, this study develops a novel composite resin sealing agent by incorporating a self-synthesized hyperbranched resin (HY) into a bisphenol A diglycidyl ether (DGEBA) matrix. The hyperbranched structure of HY endows the uncured sealing agent with excellent fluidity, exhibiting a viscosity as low as 45 mPa s at 90 degrees C. The gelation time is adjustable from 2.5 to 4.7 h at temperatures between 60 and 90 degrees C, providing a wide operational time window for field applications. The cured body demonstrates remarkable mechanical properties, including a compressive strength of 61 MPa and a bond strength of 11.8 MPa, with stress-strain curves indicating enhanced elasticity and toughness. Scanning electron microscopy (SEM)showed that the fracture surface was rough, the stripes were staggered and branched, indicating that the solidified body was a plastic fracture, and thermogravimetric (TG) analysis confirmed high thermal stability with an onset decomposition temperature of 348 degrees C. A nitrogen gas breakthrough test on a sealed cement sheath crack demonstrated a high breakthrough pressure of 4.8 MPa, significantly outperforming the unsealed sample (0.1 MPa). Meanwhile, curing kinetics parameters were determined by differential scanning calorimetry (DSC), providing a theoretical basis for curing process control. Furthermore, the mechanism analysis shows that HY endows the sealing agent solidified body with excellent load resistance through its internal cavity and high-density weak action sites. This composite resin presents a high-performance and durable solution for mitigating annular pressure problems.

To address the deterioration of cement slurry sedimentation stability caused by high temperatures in deep and ultra-deep well cementing operations, this study synthesized a terpolymer (PASH) using acrylamide, sodium 4styrenesulfonate, and omega-hydroxy polyethylene glycol ether, and then combined it with polyethyleneimine (PEI) to prepare a high-temperature suspension stabilizer (PASHE) for cement slurry. The effects of high temperature on the apparent viscosity and molecular structure of the polymer solutions were investigated, and the temperature-controlled micro-crosslinking behavior of PASHE, as well as its influence on the stability and rheology of cement slurry under high temperature conditions, were examined. The results indicate that at 200 degrees C, PASH undergoes severe hydrolysis and chain scission, leading to a significant decrease in solution viscosity. In contrast, the PASHE solution maintains relatively high viscosity and molecular weight, demonstrating strong thermal stability. Fourier-transform infrared spectroscopy, nuclear magnetic resonance, and environmental scanning electron microscopy analyses reveal that PEI and PASH in PASHE undergo a transamidation reaction at high temperatures, forming a micro-crosslinked polymers network that enhances molecular stability. The formation of this PEI-based micro-crosslinking network is triggered at approximately 180 degrees C, ensuring favorable rheological properties of the cement slurry at medium and low temperatures. Performance evaluation of cement slurry shows that at 200 degrees C and a 5 % dosage of PASHE, no solid-phase deposition occurs, the free fluid is eliminated, and the maximum density difference of the segmented cement stone is only 0.017 g/cm3 , with excellent sedimentation stability, which is beneficial to the strength development of cement stone. PASHE transcends the conventional approach of enhancing polymer thermal resistance and viscosity, it reassembles degradation fragments into a micro-crosslinked network that binds solid-phase particles, offering a novel strategy for maintaining sedimentation stability in high-temperature cementing applications.

The integrity of cement sheaths in underground gas storage wells is critically challenged by cyclic thermo-mechanical loads during frequent gas injection/production cycles. To address this, enhancing the cement's elasticity and toughness is essential. This study introduces a surface-modified waste rubber powder (MWRP), designed to significantly improve the mechanical performance of cement. MWRP was synthesized by loading a nano-SiO₂ layer onto waste rubber powder(RP) using a sol–gel process with TEOS and a silane coupling agent, creating a "dual-lock" molecular bridge at the interface. The modified powder exhibited a transition from hydrophobic (contact angle 134.4°) to hydrophilic (contact angle 68.7°), with vastly improved dispersion in water. Compared to a cement matrix with RP, that with 3

Introduction Peripheral T cell lymphoma (PTCL) is an aggressive tumor type with poor survival, whereas treatment options for relapsed and/or refractory (r/r) disease are very limited. Standard treatments have a median progression free survival (PFS) of only 3-4 months. HH2853, the novel, potent and selective dual inhibitor of Enhancer of Zeste Homolog 1 and 2 (EZH1/2), has demonstrated a clinical benefit with a favorable safety profile in Phase 1 and Phase 2 trials in solid tumors and R/R non-Hodgkin's lymphoma (NHL) previously. Here we report the efficacy and safety data from phase 1b trial of HH2853 in r/r PTCL. Methods The Phase 1b clinical trial in PTCL (CTR20221416) was conducted from July, 2022 to June 15, 2023 at 15 sites in China. This study consisted of two parts. In part 1, 3+3 dose-escalation design with three dose levels of HH2853 (300mg, 400mg, 600mg BID) was used to identify the MTD and recommended Phase II dosage (RP2D) of HH2853. Part 2 was dose expansion at two dose groups (300mg and 400mg BID). HH2853 was orally dosed until disease progression, intolerable toxicity or withdrawal from the study. Safety was evaluated according to CTCAE v5.0. Tumor assessments were performed according to LUGANO 2014 every 2 treatment cycles (28-day/cycle). A final data cut off (DCO) on June 15, 2023 was conducted for safety and efficacy assessments. To that date, there were still 25 pts (73.5%) remained on HH2853 treatment. Results In this study in r/r PTCL, 34 pts enrolled with different PTCL histology types, including AITL (14 pts, 41.2%), PTCL-NOS (11 pts, 32.4%), ALK -ALCL (4 pts,11.8%), NKT (2 pts, 5.9%), TFH (2 pts, 5.9%), SKIN-PTCL (1 pt, 2.9%). Pts were a median age of 58 years (range: 34 to 79), ECOG 0-1 (ECOG 0, 9 pts, 26.5%, ECOG 1, 25 pts, 73.5%), had a median of 2 lines (range 1 to 5) prior systemic therapies, 6 pts (17.6%) had bone marrow involvement at the baseline. With 30 pts (88.2%) having prior CHOP or CHOP-like therapy，with 14 pts (41.2%) were refractory to their last treatment. 1pts (2.9%) had undergone hematopoietic stem cell transplantation. 32 patients (92.1%) had experienced a treatment related adverse event (TRAE), 7 pts (20.6%) experienced grade ≥3 TRAE. The most common TRAEs (≥10%) were PLT decreased (14 pts, 41.2%) , anaemia (13 pts, 38.2%)，and diarrhoea (11 pts, 32.4%). The frequently reported TRAEs of grade ≥3 with an incidence of ≥10% were PLT decreased (5 pts, 14.7%) and neutrophil count decreased (4 pts, 11.8%). 8 pts (23.5%) had dose interrupted due to TRAE. 3 pts (8.8%) had dose reductions due to TRAE from 600 to 400 mg BID, 1 pts (6.3%) had dose reductions from 400 to 200 mg BID, and 1 pts (2.9%) discontinued from the study due to TRAEs. The safety profile was consistent to that had been observed in HH2853 studies. 1 pt (2.9%) at 600mg BID experienced dose limiting toxicity (DLT)due to grade 4 PLT decreased. The majority of TRAEs were reversible or clinically manageable. Among the 34 enrolled pts, 28 patients had the evaluated response, the Overall Response Rate (ORR) was 60.7% (17 pts), including 21.4% (6 pts) Complete Responses (CR), 39.3% (11 pts) Partial Responses (PR) and 14.3% (4 pts) Stable Disease (SD), contributing to an 75.0% (21 pts) Disease Control Rate (DCR). The median time to response (mTTR) was 1.87 months (95% CI: 1.77, 2.17). At DCO the median follow up of the pts in the study was 2.79 month (IQR: 1.94, 5.88). The median Duration of Response (mDOR), the median Progression Free Survival (mPFS) and the median OS (mOS) had not reached. The 3-month PFS rate was 74.44% (95%CI:53.62%,86.95%). The 6-month OS rates was 91.97% (95%CI: 71.50%, 97.93%). Conclusions The selective EZH1/2 dual inhibitor HH2853 demonstrated good safety and promising efficacy in r/r PTCL patients, indicating its potential as a therapeutic option for this difficult to treat patient population.

The data about the clinical features and outcomes of Chinese patients with peripheral T-cell lymphomas (PTCLs) are limited. This retrospective study included 1031 patients of PTCL from January 2014 to March 2022 at 21 centers in China. The clinical features, treatment patterns, and survival outcomes of the Chinese PTCL population were reported. Among the 1031 patients, 937 patients had mature T or NK cell lymphoma (91.2

During the exploration of heavy oil using the steam huff and puff method, the wellbore undergoes cyclic temperature variations, which significantly reduce the strength of cement sheath. This study incorporated volcanic rock powder into sand-cement systems to address this challenge. The cement slurries were cured at 80 degrees Cx 0.1 MPa for 14 days, followed by 7 cycles of three-day curing at 300 degrees Cx 21 MPa to replicate the thermal recovery conditions. The compressive strength and permeability of cement stones were tested. The phase compositions, micromorphology, and porosity of the cement stones were characterized by XRD, TGA, SEM, and MIP. The results showed that at 80 degrees C, the cement stones containing 4 % volcanic rock powder (VP4) reached a compressive strength of 32.8 MPa, which was 13 % greater than that of the blank specimen (VP0, 29.1 MPa). The initial permeability of VP4 (0.0166 mu m2) was 6.6 % lower than that of VP0 (0.0178 mu m2). After seven curing cycles at 300 degrees C, VP4's compressive strength was 28.2 MPa (reduced by 14.0 %), higher than the 17.3 MPa of VP0 (reduced by 40.5 %). The permeability of VP4 increased to 0.0937 mu m2 versus VP0's 0.159 mu m2. Meanwhile, VP4's porosity increased from 32.77 % to 44.38 %, while VP0's increased from 35.6 % to 52.48 %. The higher content of C-(A)-S-H gels and lower amount of Xonotlite crystals in VP4 demonstrates that the volcanic rock powder-silica sand synergistically promoted the formation of C-(A)-S-H gels and delayed their crystallization into Xonotlite, thus improving the durability of the cement sheath under high-low temperature conditions.

To address the excessive retardation of oil well cement caused by polycarboxylate dispersants (PCE), this study synthesized a zwitterionic polycarboxylate dispersant (DPC). Its molecular structure and weight were characterized using 1H nuclear magnetic resonance and gel permeation chromatography, respectively. The dispersion effect of DPC in cement slurries was evaluated by analyzing microstates, particle size distribution, Zeta potential, and rheological properties, and compared with acetone formaldehyde sulfite condensates (AFS) and conventional anionic polycarboxylate dispersants (CPC). The influence of DPC on cement hydration was studied through thickening performance, compressive strength, semi-adiabatic calorimetry, and X-ray diffraction. DPC effectively disrupted particle flocculation in cement slurry, reducing the median particle size from 34.4 μm to 10.2 μm. At a dosage of 0.20

To address the issues of high brittleness and proneness to cracking of oil well cement stone, this study developed a waterborne epoxy resin with self-emulsifying and self-crosslinking properties. Methallyl alcohol polyoxyethylene ether and acrylamide were first prepolymerized and then esterified with 1,2,4-benzenetricarboxylic anhydride. The resulting product underwent a partial ring-opening reaction with epoxy resin, ultimately obtaining the modified epoxy resin (WER). The structure of WER was characterized using FT-IR and1H NMR. The hydrophilic, self-emulsifying, and self-crosslinking properties of WER were examined, and its modification effects on the mechanical properties of oil well cement stone were evaluated. The results showed that WER exhibits excellent hydrophilicity, with a water contact angle of 25.3 degrees. It self-disperses in water to form a stable emulsion, with a median particle size of 92.7 nm, and maintains phase stability without delamination for 30 min under high-speed centrifugation at 6000 rpm. WER can cross-link and cure within 5 h at a temperature above 90 degrees C and under alkaline conditions without the need for additional curing agents. WER can effectively increase the mechanical performance of oil well cement stone. In comparison to the blank cement stone, adding 6 % WER enhances the flexural strength of cement stone by 58.64 %, the compressive strength by 32.94 %, and decreases the elastic modulus by 12.36 %. SEM analysis revealed that WER underwent cross-linking, forming an interconnected three-dimensional network structure and polymer film that binds hydration products, fills micropores and microcracks, and densifies the structure, thereby significantly increasing the mechanical strength of the cement stone. WER, with its superior self-emulsifying and self-crosslinking properties, not only simplifies the application of epoxy resin in well cementing, but also effectively enhance the mechanical properties of cement stone, is expected to become an important material for ensuring the long-term safe operation of oil and gas wells.

Currently, there is no definitive and effective treatment strategy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In recent years, studies on brentuximab vedotin (BV) and programmed cell death-1 (PD-1) monotherapy for R/R DLBCL have demonstrated significant clinical benefits. Based on this, this article retrospectively analyzes a case of R/R DLBCL with secondary hemophagocytic syndrome successfully treated with BV combined with a PD-1 monoclonal antibody and reviews the relevant literature. The patient was a 55-year-old woman who was diagnosed with stage IIE diffuse large B-cell lymphoma in June 2020. She failed to achieve complete remission during first-line treatment with the R-CHOP (rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone) regimen. After switching to the R2-GDP regimen for second-line salvage therapy, her condition continued to progress, and recurrent hemophagocytic syndrome developed. Subsequent treatment with BV combined with a PD-1 monoclonal antibody resulted in significant relief of her symptoms. As of the follow-up on 8 March 2025, the patient maintained a normal life and had no intolerable immune-related adverse effects. This study suggests that BV combined with PD-1 monoclonal antibody may exert a synergistic effect in the treatment of R/R DLBCL complicated with hemophagocytic lymphohistiocytosis (HLH).

7055 Background: Natural killer/T-cell lymphoma (NKTCL) is a unique subtype of non-Hodgkin lymphoma with aggressive disease course. Mitoxantrone hydrochloride liposome (Lipo-MIT) is a nano-drug that has been approved for relapsed/refractory (r/r) PTCL, and has shown certain efficacy and safety in a pivotal phase Ⅱ study (Cancer. 2025, e35672). Tislelizumab is a humanized immunoglobulin G4 variant monoclonal antibody against PD-1. This study aims to investigate the safety and efficacy of combining Lipo-MIT with tislelizumab in patients (pts) with r/r NKTCL. Methods: Pts with r/r NKTCL and failed asparaginase-based therapy were recruited in this single-arm, multicenter phase Ib/Ⅱ study (NCT05464433). Phase Ib was 3+3 dose escalation design with two dose levels of Lipo-MIT (16 mg/m 2 and 20 mg/m 2 , d1) plus tislelizumab 200 mg (d1, Q4W) induction therapy for up to 6 cycles, then tislelizumab 200 mg (Q3W) maintenance therapy for up to 1 year. Phase II was conducted at the recommended phase II dose (RP2D). The primary endpoints were safety and tolerability, and determination of the maximum tolerated dose (or RP2D) of Lipo-MIT in phase Ib, and the overall response rate (ORR) of phase II. Results: As of the data cut-off on January 24, 2025, a total of 40 eligible pts were enrolled (phase Ib, n=6 and phase II, n=34). The median age was 46.5 (range 22-73) years. Among the pts, 62.5% had stage III or IV and 87.5% had nasal type NKTCL. No dose-limiting toxicities (DLT) were observed in the phase Ib study, and the RP2D of Lipo-MIT was determined to be 20 mg/m 2 . The ORR and DCR were all of 100.0% (6/6, 95% CI 60.7%-100.0%) and the CR rate was 66.7% (4/6, 95% CI 27.1%-93.7%) in phase Ib. In the ongoing phase II stage, 30 pts were evaluable for efficacy. The ORR, DCR and CR rate were 70.0% (21/30, 95% CI 50.6%-85.3%), 76.7% (23/30, 95% CI 57.7%-90.1%) and 46.7% (14/30, 95% CI 28.3%-65.7%), respectively. Overall, combining data from phase Ib and phase II, the ORR was 75.0% (27/36, 95% CI 57.8%-87.9%) and the CR rate was 50.0 (18/36, 95% CI 32.9%-67.1%). Among the 15 pts who had not used PD-1 before, CR rate was 66.7% and ORR reached 80.0%. The median PFS and OS will be reported with longer follow-up. The most common grade 3/4 treatment-related adverse events (TRAEs) included leucopenia (37.5%), neutropenia (30.0%) and decreased lymphocyte count (27.5%). Notably, no cardiac events occurred during the study. Conclusions: Lipo-MIT in combination with tislelizumab demonstrated an encouraging efficacy in r/r NKTCL pts with a manageable safety profile. Clinical trial information: NCT05464433 .

Due to the hydrophobic surface of rubber particles, it is difficult to meet the self-repairing requirements of cemented cement stone microcracks under carbon dioxide oil-drive operating environment. In our research described here hydrophilic modification of butadiene-acrylonitrile polymer particle surfaces using gamma-aminopropyl triethoxysilane was conducted. The dispersive ability of the hydrophilic butadiene-polyacrylonitrile polymer particles was assessed using the contact angle test and image binarization, and the dispersion coefficients were calculated for each. A cement stone microcrack self-repairing apparatus was used to determine the microcracks self-repairing capabilities of the cement stone. Dispersion tests revealed that the contact angle of the modified polymer particles in air was 74.3 degrees, which was less than the unmodified ones, 122.3 degrees, and their dispersion coefficient in water was 55.04, which was less than the unmodified particles, 99.11, indicating an 80% improvement in dispersion performance in water. The cement stone outlet flow rate of M-NBR cement stone with just formed cracks was 3800 mL/min, and after being repaired with 8 MPa carbon dioxide at 80 degrees C for 72 h, the cement stone outlet flow rate decreased to 87 mL/min. After repairing, the width of the cement stone microcrack was significantly reduced compared to the initial 0195 mm, because of the action of filling by swelling of M-NBR particles. Mechanism analysis showed that after the microcracks were created in the supercritical carbon dioxide environment, the modified butadiene-acrylonitrile polymer particles swelled at the microcracks to fill the voids and repair the microcracks in the cement stone.

JMT601 is a bi-specific left-right asymmetrical fusion protein comprised of a high CD20 binding affinity Fab arm and a low CD47 binding fragment SIRPα, without binding CD20-negative lymphoma cells, RBCs and platelet. JMT601 was more effective in multiple human B-cell lymphoma models than conventional CD20-targeted antibodies monotherapy and in combination with SIRPα, but without severe anemia and thrombocytopenia. Here we present the preliminary safety and efficacy of JMT601 in patients with relapse/refractory CD20 positive B-cell NHL. Patients aged 18-70 years with histologically confirmed B-cell NHL (including diffused large B-cell lymphoma, DLBCL; follicular lymphoma, FL; mantle cell lymphoma, MCL), relapsed or refractory disease after ≥2 prior lines of therapy, ECOG performance score 0-2 and at least one measurable/evaluable lesion as per Lugano 2014 were recruited. This study consisted of dose-escalation part (1) and dose-expansion part (2). Part 1 was 3+3 dose-escalation design with eight dose levels of JMT601 (0.3, 1, 3, 6, 12, 20, and 30 mg/kg) intravenously administered weekly until disease progression, intolerable toxicity, or consent withdrawal. Part 2 was dose expansion at the recommended dose in selected tumor types. The primary endpoints were safety and tolerability. At the cut-off date of August 20, 2024, 36 eligible patients (23 males; Lugano Classification III-IV disease: 58.3%) were enrolled (30 in part 1, 6 in part 2), including 31 DLBCL, 4 FL and 1 MZL. Median age was 59.0 (range, 24-75). 27 patients (75.0%) had ≥3 prior lines of therapy. 27 patients (75.0%) were refractory to prior rituximab-based combination therapy. One dose-limiting toxicity (grade 4 thrombocytopenia) occurred at 12 mg/kg dose level, MTD was not reached. Treatment-related adverse events (TRAEs) of any grade occurred in 31 (86.1%) patients, in which 16 (44.4%) were ≥ grade 3. The most common ≥ grade 3 TRAEs were neutropenia (19.4%), thrombocytopenia (13.9%), leukopenia (11.1%), lymphocytopenia (8.3%), hypertriglyceridemia (5.6%), amenia (5.6%) and infectious pneumonia (5.6%). 9 (25.0%) patients experienced serious adverse events (SAEs), of which 3 had treatment related SAEs (2 thrombocytopenia and 1 infectious pneumonia). One patient died due to disease progression, which was not related to JMT601 treatment judged by the investigator. 32 patients were efficacy evaluable, objective response rate (ORR) was 25.0% (8/32, 95% CI 11.5-43.4), disease control rate (DCR) was 50%. ORR and DCR were 28.0% (7/25) and 52.0% (13/25) for DLBCL, 25.0% (1/4) and 50.0% (2/4) for FL/MZL, respectively. JMT601 had an encouraging anti-tumor effect in relapse/refractory CD20 positive B-cell NHL patients with acceptable safety profiles. This trial is registered at ClinicalTrials.gov (NCT06725524). Weili Zhao, Shu Cheng, Wenjuan Yu, Juying Wei, Yunhong Huang, Yunfei Hu, Qiangxing Zeng, Lier Lin, Zhenyu Zhao, Mengling Duan, Yueqing Chen, Zhigang Peng, Haiyan Yang, Ming Jiang, Fei Li, Yulan Zhou, Li Wang, Pengpeng Xu, Huijuan Zhong, Guodong Luan, Wenfeng Mao, Yanyan Xiao, Yitao Wang, Lifang Shu. First-in-human trial of JMT601, a bispecific fusion protein targeting CD47 and CD20, in patients with relapse/refractory CD20 positive B-cell non-Hodgkin lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT060.

BackgroundThis study aimed to elucidate the treatment outcomes and prognosis of angioimmunoblastic T-cell lymphoma (AITL) patients in a real-world setting.ObjectivesThe clinical efficacy of new drug applications was evaluated, alongside the predictive accuracy of prognostic models, to inform future research.MethodsIn this study, 82.9% of patients received a CHOP-like regimen, while 36.4% also received chidamide. We assessed the prognostic models’ predictive power using the Cox proportional hazards model and concordance index (C-index).ResultsThe median age of the patients in this study was 62.0 years, with 2-year progression-free survival (PFS) and overall survival (OS) rates of 36.1% and 60.3%, respectively. Complete response (CR) rates in first-line treatments were 21.6% for the chidamide-containing group and 28.1% for the chidamide-free group. The AITL scores, PIAI scores, and Chinese AITL scores demonstrated superior C-index values, with the Chinese AITL score providing the most distinct risk stratification. Advanced age (over 70 years), bone marrow involvement, and CD7 negativity were identified as significant prognostic factors associated with poorer PFS in both univariate and multivariate analyses. A novel prognostic model, the South China AITL Score, was constructed by combining these three factors, stratifying patients into low-risk and high-risk groups, with 5-year PFS rates of 81.5% and 34.6%, respectively. This model was successfully validated in an independent cohort.ConclusionsThe prognosis of AITL in real-world settings is poor, and the addition of chidamide did not show improvement in remission rates or survival. Our novel prognostic model, along with the Chinese AITL score, may enhance the identification of Chinese patients at varying risks for chemotherapy. Furthermore, the pathological marker CD7 is anticipated to emerge as a significant biomarker for the prognostic evaluation of AITL.

As the number of ultra-deep wells increases, maintaining the suspension stability of cement slurry at ultra-high temperatures becomes increasingly challenging; the development of a suspension stabilizer suitable for ultra-high temperature environments is imperative. Therefore, this study synthesized a temperature-resistant polymer suspension stabilizer (LHAP) using 2-acrylamide-2-methylpropanesulfonic acid (AMPS), N, N-dimethyl acrylamide (DMAA), 4-acryloylmorpholine (ACMO), and quaternary ammonium cationic hydrophobic long-chain monomer hexadecyl dimethylallyl ammonium chloride (DMAAC-16) as raw materials. It was applied to maintain the suspension stability of cement slurry at ultra-high temperatures. The molecular structure and molecular weight of LHAP were characterized and tested using infrared spectroscopy, nuclear magnetic hydrogen spectroscopy, and Ubbelohde viscometer. The thermal stability and viscosity-temperature performance of LHAP were measured using thermogravimetric analysis and rheometer, respectively. Through the segmented density difference testing of cement stone columns, the suspension stability effect of LHAP on cement slurry under high temperature was evaluated. The suspension stabilization mechanism of LHAP was studied through fluorescence probe testing, variable temperature UV visible light testing, variable temperature particle size distribution testing, Zeta potential analysis, Environmental Scanning Electron Microscopy (ESEM) analysis, and scanning electron microscopy (SEM) analysis. The results indicated that the polymer suspension agent LHAP had excellent temperature resistance, and the molecules didn't undergo significant thermal degradation below 302 degree celsius. At high temperatures of 220 degree celsius, LHAP could maintain the suspension stability of cement slurry, and the segmented density difference of cement columns was less than 0.01 g/cm(3). Mechanism analysis revealed that in addition to enhancing temperature resistance by introducing sulfonic acid groups and rigid rings, LHAP also effectively maintains the stability of the slurry suspension at ultra-high temperatures by coordinating electrostatic interactions and molecular associations. LHAP can effectively solve the settlement instability problem of cement slurry under ultra-high temperature, which is beneficial for improving the safety and quality of cementing construction in ultra-deep wells.

In order to improve the compatibility and dispersibility of polypropylene fiber (PPF) in oil well cement and enhance the mechanical properties of cementing cement sheath, the surface modification of PPF was carried out in this study. After surface impurity removal of PPF, reaction of catechol with polyamines, and subsequent treatment with γ- aminopropyltriethoxysilane (KH-550) and Ethyl orthosilicate (TEOS), modified polypropylene fiber (MPF) was obtained. The MPF was characterized and analyzed using FTIR, XPS, SEM, and EDS, showing a transformation in the surface properties of the fibers. The most significant change was that the contact angle between MPF and water decreased from 123.87 ° to 46.32 °, marking the successful transition of the fiber from hydrophobicity to hydrophilicity. Image analysis showed that the dispersion of MPF improved significantly. The dispersion coefficient of MPF in water and cement stone was increased by 86.90% and 14.48% compared with PPF, respectively. The effect of MPF on mechanical properties of oil well cement stone was studied. The comparative analysis results showed that MPF can significantly improve the flexural and compressive strength of the cement matrix. The flexural and compressive strength of cement stone mixed with MPF were increased by 10.25% and 6.43%, respectively, compared to cement stone mixed with PPF. SEM, MIP, and fiber single fiber pull-out experiments showed that the porosity of cement stone added with MPF was lower, the rough surface structure of MPF enhanced the bonding between fibers and cement stone, and the bridging effect of fibers in cement stone ultimately improved the mechanical properties of oil well cement stone.